Novartis's Stock Selloff Looks Overdone

Dow Jones

Sep 09

0823 GMT - Novartis's stock selloff on the failure of a neuromuscular drug in a clinical trial looks overdone and upcoming study results could be more positive for the Swiss drugmaker, Citi analysts say in a research note. The company reiterated its 2025-2030 outlook and trial setbacks for experimental neuromuscular and heart drugs del-desiran and pelacarsen are partially mitigated by the success of its remibrutinib medicine in a multiple sclerosis study, the analysts say. Full data for the MS study and results from another trial for the same drug in skin condition hidradenitis suppurativa could play in Novartis's favor, they add. Citi cuts its target price on Novartis stock to 135 Swiss francs from 142 francs. Shares fall 1.1% to 110.54 francs, after closing 11% lower Tuesday.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/news/2666854435"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2666854435\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2666854435?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-09 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2666854435","market":"nz","top_or_hot":-1,"title":"Novartis's Stock Selloff Looks Overdone","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>0823 GMT - Novartis's stock selloff on the failure of a neuromuscular drug in a clinical trial looks overdone and upcoming study results could be more positive for the Swiss drugmaker, Citi analysts say in a research note. The company reiterated its 2025-2030 outlook and trial setbacks for experimental neuromuscular and heart drugs del-desiran and pelacarsen are partially mitigated by the success of its remibrutinib medicine in a multiple sclerosis study, the analysts say. Full data for the MS study and results from another trial for the same drug in skin condition hidradenitis suppurativa could play in Novartis's favor, they add. Citi cuts its target price on Novartis stock to 135 Swiss francs from 142 francs. Shares fall 1.1% to 110.54 francs, after closing 11% lower Tuesday.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis's Stock Selloff Looks Overdone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis's Stock Selloff Looks Overdone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-09-09 16:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>0823 GMT - Novartis's stock selloff on the failure of a neuromuscular drug in a clinical trial looks overdone and upcoming study results could be more positive for the Swiss drugmaker, Citi analysts say in a research note. The company reiterated its 2025-2030 outlook and trial setbacks for experimental neuromuscular and heart drugs del-desiran and pelacarsen are partially mitigated by the success of its remibrutinib medicine in a multiple sclerosis study, the analysts say. Full data for the MS study and results from another trial for the same drug in skin condition hidradenitis suppurativa could play in Novartis's favor, they add. Citi cuts its target price on Novartis stock to 135 Swiss francs from 142 francs. Shares fall 1.1% to 110.54 francs, after closing 11% lower Tuesday.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002141913.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2666854435","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2666854435","pubTimestamp":1788942240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0823 GMT - Novartis's stock selloff on the failure of a neuromuscular drug in a clinical trial looks overdone and upcoming study results could be more positive for the Swiss drugmaker, Citi analysts say in a research note. The company reiterated its 2025-2030 outlook and trial setbacks for experimental neuromuscular and heart drugs del-desiran and pelacarsen are partially mitigated by the success of its remibrutinib medicine in a multiple sclerosis study, the analysts say. Full data for the MS study and results from another trial for the same drug in skin condition hidradenitis suppurativa could play in Novartis's favor, they add. Citi cuts its target price on Novartis stock to 135 Swiss francs from 142 francs. Shares fall 1.1% to 110.54 francs, after closing 11% lower Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","MEDX":"HORIZON KINETICS MEDICAL ETF","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","PPH":"VanEck Pharmaceutical ETF","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4585":"ETF&股票定投概念","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4578":"CAR-T","NVS":"诺华","BK4588":"碎股","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4007":"制药","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"诺华的股票抛售看起来过度了","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9,"MEDX":0.6,"PPH":0.6},"content_text":"0823 GMT - Novartis's stock selloff on the failure of a neuromuscular drug in a clinical trial looks overdone and upcoming study results could be more positive for the Swiss drugmaker, Citi analysts say in a research note. The company reiterated its 2025-2030 outlook and trial setbacks for experimental neuromuscular and heart drugs del-desiran and pelacarsen are partially mitigated by the success of its remibrutinib medicine in a multiple sclerosis study, the analysts say. Full data for the MS study and results from another trial for the same drug in skin condition hidradenitis suppurativa could play in Novartis's favor, they add. Citi cuts its target price on Novartis stock to 135 Swiss francs from 142 francs. Shares fall 1.1% to 110.54 francs, after closing 11% lower Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}